A Study to Evaluate the Safety & Pharmacokinetics ABBV-399 in Japanese

Updated 06/21/2024

Status Completed

Clinical Trial Summary

An open-label, dose-escalation study designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-399 in participants with advanced solid tumors.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03311477
Study type	Interventional
Source	AbbVie
Contact
Status	Completed
Phase	Phase 1
Start date	November 6, 2017
Completion date	March 4, 2019

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03234712` - A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)	Phase 1
	Completed	`NCT02955251` - A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors	Phase 1
	Completed	`NCT03071757` - A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors	Phase 1
	Recruiting	`NCT04417465` - First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors	Phase 1
	Terminated	`NCT03145909` - A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)	Phase 1
	Completed	`NCT04196283` - A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	Phase 1
	Active, not recruiting	`NCT02099058` - A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors	Phase 1
	Active, not recruiting	`NCT04721015` - Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors	Phase 1
	Active, not recruiting	`NCT02988960` - A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors	Phase 1
	Recruiting	`NCT03821935` - Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors	Phase 1
	Recruiting	`NCT05929235` - A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma	Phase 1